No Data
No Data
Should We Be Delighted With TransMedics Group, Inc.'s (NASDAQ:TMDX) ROE Of 16%?
How Is The Market Feeling About TransMedics Gr?
Why Transmedics Plunged in December
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $125
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $90
Piper Sandler Sticks to Its Buy Rating for TransMedics Group (TMDX)